Salignostics

Key People

• Prof. Aharon Palmon - Co-founder and Vice President for Research and Development
• Dr. Omer Deutsch - Co-founder and CEO
• Dr. Guy Krief - Co-founder and Deputy CEO
• Dr. Raluca Cohen - Co-founder and Chief Scientific Officer
• Dr. Yoav Neumann - Co-founder and Senior Researcher

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The founding team comprises experienced researchers with extensive backgrounds in saliva research and diagnostics.

Salignostics was founded by a team of researchers from the Hebrew University of Jerusalem, including Prof. Aharon Palmon, a world-renowned saliva researcher, and Dr. Omer Deutsch, the CEO. Their combined experience in saliva diagnostics provides a strong foundation for the company's endeavors.

Clinical Need

Aspect: Very Strong
Summary: Saliva-based diagnostics offer a non-invasive, rapid, and user-friendly alternative to traditional testing methods.

Saliva diagnostics provide a painless and accessible method for disease detection, addressing the need for patient-friendly testing solutions. This approach is particularly beneficial for populations such as children, the elderly, or those with needle-related anxiety.

Competition

Aspect: Somewhat crowded
Summary: The saliva diagnostics market includes several established players offering diverse testing solutions.

Key competitors in the saliva diagnostics market include Thermo Fisher Scientific, Neogen Corporation, and Abbott. However, Salignostics' development of unique products like Salistick, the world's first saliva-based pregnancy test, differentiates it from competitors.

Technical Challenge

Aspect: Predictable
Summary: The development of saliva-based diagnostics involves manageable technical challenges with established research backing.

Salignostics' team has extensive experience in saliva research, enabling them to address technical challenges effectively. Their proprietary platform has already been used to develop and market several rapid tests, including home COVID-19 tests and Salistick.

Patent

Aspect: Strong
Summary: Salignostics has developed proprietary technologies for saliva-based diagnostics.

The proprietary knowledge of Salignostics' founders enabled the company to develop user-friendly products to accurately detect a range of physiological conditions, including pregnancy and COVID-19, based on simple saliva samples.

Financing

Aspect: Medium
Summary: Salignostics has secured significant funding to support its development and commercialization efforts.

In April 2022, Salignostics closed an $8 million Series A financing round from private investors headed by angel investor Avigdor Orlinsky. The capital raised supports development, commercialization, and marketing efforts, as well as the launch of a new plant in Northern Israel.

Regulatory

Aspect: 510k/PMA
Summary: Salignostics has achieved regulatory approvals for its products in multiple regions.

Salistick, the world's first saliva-based pregnancy test, has received CE approval and was recognized by TIME magazine as one of the Best Inventions of 2023. Additionally, the product has obtained approval from Australia's Therapeutic Goods Administration (TGA), allowing entry into the Australian and New Zealand markets.

Opportunity Rollup

Odds of Success

3.65

Peak Market Share

4.9

Segment CAGR

4.7%

Market Segment

In Vitro Diagnostics

Market Sub Segment

Saliva-Based Diagnostics

Key Takeaway

Salignostics' innovative saliva-based diagnostics address a growing demand for non-invasive testing, positioning the company favorably in a competitive market with significant growth potential.